This week is a special two-part episode focusing on last week’s controversial — some say inflammatory — decision to approve aducanumab, a new Alzheimer’s drug. In these episodes, I talk with two Alzheimer’s experts with vastly different viewpoints on the news. First up: Dennis J. Selkoe, a physician and scientist whose research is at the core of how Aduhelm works.
Episode 19, Part 1: An original believer on the aducanumab decision | First Opinion Podcast - Listen or read transcript on Metacast
